| 1975-09 |
Establishment of Japan Chemical Research Co., Ltd. |
| 1975-09 |
Founded Nippon Chemical Research |
| 1975-10 |
Established Mikage Factory in Higashinada-ku, Kobe City, Hyogo Prefecture |
| 1975-10 |
Opened Mikage Plant in Higashinada-ku, Kobe, Hyogo |
| 1976-12 |
Established a method for refining urokinase (thrombolytic agent) raw material |
| 1976-12 |
Established a purification method for urokinase drug substance, a thrombolytic agent |
| 1977-04 |
Set up a research institute within Mikage Factory |
| 1977-04 |
Opened a research laboratory at the Mikage Plant |
| 1981-10 |
Relocated the research institute to Chuo-ku, Kobe City, Hyogo Prefecture |
| 1981-10 |
Relocated the research laboratory to Chuo-ku, Kobe, Hyogo |
| 1983-10 |
Obtained manufacturing approval for urokinase preparations and raw solutions |
| 1983-10 |
Received manufacturing approval for urokinase drug product and bulk solution |
| 1985-01 |
Obtained import approval for human growth hormone preparation "Growlum" |
| 1985-01 |
Received import approval for Growlum, a human growth hormone product |
| 1985-07 |
Opened Tokyo Office in Shibuya-ku, Tokyo |
| 1985-07 |
Opened the Tokyo Office in Shibuya-ku, Tokyo |
| 1986-06 |
Established Nishishin Factory in Nishishin Industrial Park, Nishi-ku, Kobe City, Hyogo Prefecture |
| 1986-06 |
Opened the Seishin Plant in Nishi-ku, Kobe, Hyogo (Seishin Industrial Park) |
| 1986-12 |
Relocated the research institute adjacent to Nishishin Factory |
| 1986-12 |
Relocated the research laboratory to a site adjacent to the Seishin Plant |
| 1992-10 |
Registered as a over-the-counter listed stock with the Japan Securities Dealers Association |
| 1992-10 |
Registered as an over-the-counter stock with the Japan Securities Dealers Association |
| 1993-04 |
Obtained manufacturing approval for genetically engineered human growth hormone preparation "Growject® 4IU" |
| 1993-04 |
Received manufacturing approval for GROWJECT™ Injection 4IU, a recombinant human growth hormone product |
| 1993-06 |
Relocated headquarters to current location at 3-19 Kasugacho, Ashiya-shi, Hyogo Prefecture |
| 1993-06 |
Relocated headquarters to Kasuga-cho, Ashiya, Hyogo (current location) |
| 1993-09 |
Launched needle-free pressure injector "TwinJector® EZ" for "Growject®" |
| 1993-09 |
Launched TWINJECTOR® EZ, a needle-free pressure injector for GROWJECT™ |
| 1993-10 |
Constructed and relocated research institute to Kobe High-Tech Park, Nishi-ku, Kobe City, Hyogo Prefecture |
| 1993-10 |
Relocated the research laboratory to Nishi-ku, Kobe, Hyogo (Kobe High-Tech Park) |
| 1994-03 |
Obtained manufacturing approval for urinastatin raw solution "JCR" |
| 1994-03 |
Received manufacturing approval for Ulinastatin Bulk Solution “JCR,” a protease inhibitor drug substance |
| 1994-03 |
Approval for manufacturing of Urinastatin raw material "JCR" (protein-degrading enzyme inhibitor raw material) |
| 1994-06 |
Established a West Kobe Tech Park factory in Nishiku, Kobe City, Hyogo Prefecture |
| 1994-06 |
Opened the Seishin South Plant in Kobe High-Tech Park |
| 1995-03 |
Listed on the Osaka Securities Exchange Second Section |
| 1995-03 |
Listed on the Second Section of the Osaka Securities Exchange |
| 1995-06 |
Established 'JCR Biopharmaceuticals, Inc.' in the United States |
| 1995-06 |
Established JCR Biopharmaceuticals, Inc. in the United States |
| 1995-08 |
Established a joint venture 'Jiexi Pharmaceutical Co., Ltd.' with Beijing Shanhai Medical and Health Development Co., Ltd. in China |
| 1995-08 |
Established Jiexi Pharmaceutical Co., Ltd. in China through a joint venture with Beijing Shanhe Medical & Health Development Co., Ltd., wholly owned by Beijing Hospital |
| 1995-08 |
Established a joint venture "Jiexi Pharmaceutical Co., Ltd." with Beijing Shanhai Medical and Health Development Co., Ltd. (100% owned by Beijing Hospital, China) |
| 1996-11 |
Started import and sales of injection accessories 'Conijector® Pen' for 'Glowject®' |
| 1996-11 |
Began importing and marketing the KONYJECTOR® Pen, an injection aid for GROWJECT™ |
| 1997-02 |
Established a medical device sales company 'Family Health Rental Co., Ltd.' in Chuo Ward, Kobe City, Hyogo Prefecture |
| 1997-02 |
Established Family Health Rental Co., Ltd., a medical device sales company, in Chuo-ku, Kobe, Hyogo |
| 1999-01 |
Started sales partnership with Sumitomo Pharmaceutical Co., Ltd. for recombinant human growth hormone preparation 'Glowject® Inje4IU' |
| 1999-01 |
Entered into a marketing alliance with Sumitomo Pharmaceuticals Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for GROWJECT™ Injection 4IU |
| 1999-01 |
Started sales partnership with Sumitomo Pharmaceutical Co., Ltd. (now Sumitomo Pharma Co., Ltd.) for recombinant human growth hormone preparation "Growject® 4IU" |
| 1999-04 |
Inherited manufacturing approval for leukopenia treatment 'Leukoprool®' from Morinaga Milk Industry Co., Ltd. |
| 1999-04 |
Assumed manufacturing approval for Leukoprol®, a treatment for leukopenia, from Morinaga Milk Industry Co., Ltd. |
| 1999-10 |
Obtained manufacturing approval for 'Glowject® Inje24IU' and 'Glowject® BC24' |
| 1999-10 |
Received manufacturing approval for GROWJECT™ Injection 24IU and GROWJECT™ BC24 |
| 1999-12 |
Obtained additional indication approval for 'Glowject® Inje4IU' for 'short stature due to Turner syndrome without epiphyseal closure' |
| 1999-12 |
Received approval for an additional indication for GROWJECT™ Injection 4IU for short stature in Turner syndrome without closed epiphyses |
| 2000-05 |
Established Kobe Factory in Nishiku, Kobe City, Hyogo Prefecture |
| 2000-05 |
Opened the Kobe Plant in Kobe High-Tech Park |
| 2000-07 |
Launched recombinant human growth hormone preparations 'Glowject® Inje1.33mg,' 'Glowject® Inje8mg,' 'Glowject® BC8mg,' and pen-type injector 'Glowject® Pen' |
| 2000-07 |
Launched GROWJECT™ Injection 1.33mg, GROWJECT™ Injection 8mg, GROWJECT™ BC8mg, and the GROWJECT™ Pen injector |
| 2000-10 |
Established 'Chromatec Co., Ltd.' in Nishinomiya City, Hyogo Prefecture for research and medical device sales |
| 2000-10 |
Established Chromatec Co., Ltd., a distributor of research and medical equipment, in Nishinomiya, Hyogo |
| 2001-09 |
Launched 'Glowject® Pen0.1mg,' a pen-type injector with mg increments to accommodate formulation unit changes |
| 2001-09 |
Launched GROWJECT™ Pen 0.1mg, a pen injector with 0.1 mg increments reflecting revised product specifications |
| 2004-08 |
Launched 'TwinJector® EZ II,' a needleless pressure injector for 'Glowject®' |
| 2004-08 |
Launched TWINJECTOR® EZ II, a needle-free pressure injector for GROWJECT™ |
| 2005-04 |
Established a clinical trial drug manufacturing center (current Moritani Factory) in Nishiku, Kobe City, Hyogo Prefecture |
| 2005-04 |
Opened the Clinical Trial Product Manufacturing Center (now Murotani Plant) in Kobe High-Tech Park |
| 2005-09 |
Launched an improved version of 'Glowject® Pen,' a dedicated injector for 'Glowject®,' called 'BD PenJector™2' |
| 2005-09 |
Launched the BD PenJector™ 2, an improved injector for GROWJECT™ |
| 2006-06 |
Started sales of imported raw material 'Paclitaxel' for anticancer agents to Nippon Kayaku Co., Ltd. |
| 2006-06 |
Began marketing imported paclitaxel drug substance, an anticancer agent, to Nippon Kayaku Co., Ltd. |
| 2006-10 |
Launched 'Glowject®,' an electric injection device dedicated to 'Glowject®' |
| 2006-10 |
Launched the GROWJECTER®, an electric injector for GROWJECT™ |
| 2008-04 |
Established Moritani Factory in Nishiku, Kobe City, Hyogo Prefecture (reorganized from clinical trial drug manufacturing center) |
| 2008-04 |
Opened the Murotani Plant in Kobe High-Tech Park, reorganized from the Clinical Trial Product Manufacturing Center |
| 2009-07 |
Approval for additional efficacy of genetically modified human growth hormone preparation "Growject®" for "Adult Growth Hormone Deficiency" |
| 2009-07 |
Established Kobe West Plant in Kobe Tech Park, Nishiku, Kobe City, Hyogo Prefecture, as a manufacturing plant for human mesenchymal stem cells |
| 2009-07 |
Received approval for an additional indication for GROWJECT™ for adult growth hormone deficiency |
| 2009-07 |
Opened the Kobe Nishi Plant in Kobe High-Tech Park as a manufacturing facility for human mesenchymal stem cells |
| 2009-08 |
Launched "BD Penjector™3", the successor to the dedicated injector for "Growject®" "BD Penjector™2" |
| 2009-08 |
Launched the BD PenJector™ 3, the successor to the BD PenJector™ 2 injector for GROWJECT™ |
| 2010-05 |
Launched the renal anemia treatment drug "Epoetin Alpha BS Injection "JCR"" |
| 2010-05 |
Launched Epoetin Alfa BS Injection “JCR,” Japan’s first biosimilar for the treatment of renal anemia |
| 2010-05 |
Launched the first domestically produced biosimilar, erythropoiesis-stimulating agent "Epoetin Alpha BS" |
| 2011-03 |
Listed on the Second Section of the Tokyo Stock Exchange |
| 2011-03 |
Listed on the Second Section of the Tokyo Stock Exchange |
| 2011-10 |
Established "JCR Engineering Inc.", which manages pharmaceutical manufacturing equipment, facilities, and machinery, in Kobe Tech Park, Nishiku, Kobe City, Hyogo Prefecture |
| 2011-10 |
Established JCR Engineering Co., Ltd. in Kobe High-Tech Park to manage pharmaceutical manufacturing facilities, equipment, and instruments |
| 2012-07 |
Launched the successor to the electric injector for "Growject®" "Growjector®2" |
| 2012-07 |
Launched GROWJECTER® 2, the successor to the GROWJECTER® electric injector for GROWJECT™ |
| 2012-08 |
Approval for additional efficacy of genetically modified human growth hormone preparation "Growject®" for "SGA short stature without epiphyseal closure" |
| 2012-08 |
JCR receives an Approval for Expanded Indication of Growject™ in Short Stature due to Small-for-Gestational Age (SGA) |
| 2012-08 |
JCR receives an Approval for Expanded Indication of Growject™ in Short Stature due to Small-for-Gestational Age (SGA) |
| 2013-05 |
Established Kobe Active Pharmaceutical Ingredient Plant in Kobe Tech Park, Nishiku, Kobe City, Hyogo Prefecture |
| 2013-05 |
Opened the Kobe API Plant in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park) |
| 2013-11 |
Listed on the First Section of the Tokyo Stock Exchange |
| 2013-11 |
Listed on the First Section of the Tokyo Stock Exchange |
| 2014-01 |
Changed company name to JCR Pharma Co., Ltd. |
| 2014-01 |
Renamed to JCR Pharmaceuticals Co., Ltd. |
| 2015-08 |
Established Kobe Logistics Center in Kobe Tech Park, Nishiku, Kobe City, Hyogo Prefecture |
| 2015-08 |
Opened the Kobe Logistics Center in Nishi-ku, Kobe, Hyogo Prefecture (Kobe High-Tech Park) |
| 2015-11 |
Established market research company "JCR INTERNATIONAL SA" in Switzerland |
| 2015-11 |
Established JCR INTERNATIONAL SA, a market research company, in Switzerland |
| 2016-02 |
Launched Japan's first allogeneic regenerative medicine product "Temcell®HS Injection" |
| 2016-02 |
Launched TEMCELL™ HS Inj., Japan’s first allogeneic regenerative medicine product. |
| 2016-04 |
Established clinical trial drug manufacturing center and cell processing center within the research institute site |
| 2016-04 |
Opened a Clinical Trial Drug Manufacturing Center and a Cell Processing Center within the research institute premises |
| 2016-06 |
Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product “Growject™ |
| 2016-06 |
Obtained manufacturing and marketing approval for the liquid formulation of the recombinant human growth hormone product “Growject™" |
| 2016-08 |
Obtained approval for manufacturing and sales of liquid formulation of "Growject®" |
| 2017-01 |
Launched "Growjector®L", an electric injector dedicated to "Growject®" liquid formulation |
| 2017-01 |
Launched “Growjecter® L,” an electric injection device dedicated to the liquid formulation of “Growject™ |
| 2017-01 |
Launched “Growjecter® L,” an electric injection device dedicated to the liquid formulation of “Growject™" |
| 2018-01 |
Established JCR USA, Inc., a global management company for clinical development in the United States |
| 2018-01 |
Established JCR USA, Inc. in the United States to oversee clinical development |
| 2018-11 |
Launched "Agalsidase Beta BS IV" as the company's first lysosomal storage disease enzyme preparation |
| 2018-11 |
Launched Agalsidase Beta BS Intravenous Infusion “JCR,” the Company’s first enzyme replacement therapy for lysosomal storage disorders |
| 2018-11 |
Launched the long-acting erythropoiesis-stimulating agent “Darbepoetin Alfa BS Injection ‘JCR’ |
| 2018-11 |
Launched the sustained-release erythropoiesis-stimulating agent "Darbepoetin Alpha BS" |
| 2018-11 |
Launched the long-acting erythropoiesis-stimulating agent “Darbepoetin Alfa BS Injection ‘JCR" |
| 2020-04 |
Acquired all shares of U.S. pharmaceutical research and development company "ArmaGen, Inc." |
| 2020-04 |
Merged with Family Health Rental Corporation |
| 2020-04 |
Acquired all shares of ArmaGen, Inc., a U.S. biopharmaceutical R&D company |
| 2020-04 |
Absorbed and merged Family Health Rental Co., Ltd. |
| 2020-09 |
Brazilian Federal Republic-based clinical operations, pharmaceutical affairs, and development company JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA. has commenced business activities |
| 2020-09 |
JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA. commenced operations |
| 2020-10 |
Co-developed the smartphone application software "Melon Diary®" for the dedicated injector "Growject®L" of "Growject®" with PHC Corporation |
| 2020-10 |
Co-developed Meron Diary®, a smartphone app for the GROWJECTER® L injector for GROWJECT™, with PHC Corporation |
| 2020-12 |
Concluded a contract with AstraZeneca K.K. for manufacturing the original solution of the COVID-19 vaccine "AZD1222" in Japan |
| 2020-12 |
Entered into a manufacturing services agreement with AstraZeneca K.K. for domestic drug substance production of the COVID-19 vaccine AZD1222 |
| 2021-01 |
Established a bio-research center in Nishi-ku, Kobe City, Hyogo Prefecture (Kobe High-Tech Park) |
| 2021-01 |
Opened the Bioresearch Center in Kobe High-Tech Park |
| 2021-05 |
Launched the genetically engineered Mucopolysaccharidosis Type II treatment drug "Izargo®: Intravenous infusion 10mg" in Japan |
| 2021-05 |
Launched IZCARGO™ for I.V. Infusion 10mg in Japan |
| 2022-02 |
At the "WORLDSymposium™ 2022," the genetically engineered Mucopolysaccharidosis Type II treatment drug "Izargo®: Intravenous infusion" received the New Treatment Award |
| 2022-02 |
IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLDSymposium™ 2022 |
| 2022-02 |
IZCARGO™ for Intravenous Infusion received the New Treatment Award at WORLD : Symposium : ™ 2022 |
| 2022-04 |
Transitioned from the First Section of the Tokyo Stock Exchange to the Prime Market due to market classification review |
| 2022-04 |
Transferred the sales of "Agalsidase Beta BS Intravenous Infusion 'JCR'" to Sumitomo Pharma Co., Ltd. |
| 2022-04 |
Moved from the First Section to the Prime Market of the Tokyo Stock Exchange following the market restructuring |
| 2022-04 |
Transferred marketing of Agalsidase Beta BS Intravenous Infusion “JCR” to Sumitomo Pharma Co., Ltd. |
| 2022-08 |
Established "JCR Luxembourg S.A." in the Grand Duchy of Luxembourg |
| 2022-08 |
Established JCR Luxembourg S.A. as a European base for global distribution management |
| 2022-08 |
Established "JCR Luxembourg S.A." as the European base for global distribution management of the Grand Duchy of Luxembourg |
| 2022-09 |
Established "JCR Europe B.V." in the Kingdom of the Netherlands as a global management company for clinical development |
| 2022-09 |
Established JCR Europe B.V. in the Netherlands to oversee clinical development |
| 2022-09 |
Selected for the Ministry of Economy, Trade and Industry’s program to strengthen biopharmaceutical manufacturing infrastructure for vaccine production |
| 2022-10 |
Established "AlliedCel Inc." in Chuo-ku, Kobe City, Hyogo Prefecture, jointly with Sysmex Corporation, to conduct research and development of regenerative medicine products |
| 2022-10 |
Acquired shares of Taiwanese biopharmaceutical manufacturing and development contract company Mycenax Biotech Inc. |
| 2022-10 |
Established AlliedCel Corporation with Sysmex Corporation to conduct R&D on regenerative medicine products |
| 2022-10 |
Acquired shares of Mycenax Biotech Inc., a Taiwanese biopharmaceutical CDMO |
| 2022-11 |
Established Kobe Science Park Center in Nishi-ku, Kobe City, Hyogo Prefecture |
| 2022-11 |
Opened the Kobe Science Park Center in Kobe Science Park |
| 2023-06 |
Obtained approval for the efficacy addition of "Growth hormone" for "Short stature in SHOX deficiency without epiphyseal closure" |
| 2023-06 |
Received approval for an additional indication for GROWJECT™ for short stature associated with SHOX deficiency without closed epiphyses |
| 2023-09 |
Launched the new "Growject® Duo" electric injector for "Growject®" co-developed with PHC Corporation |
| 2023-09 |
Launched GROWJECTER® Duo, a new electric injector for GROWJECT™, co-developed with PHC Corporation |
| 2025-05 |
Revised corporate philosophy and core values |
| 2025-05 |
Revised the corporate philosophy and core values |
| 2025-05-09 |
Revised the corporate philosophy and core values : 9 : Adopted the corporate slogan “Life is Rare” |
| 2025-09 |
Established the corporate slogan "Life is Rare" |
| 2025-09 |
Adopted the corporate slogan “Life is Rare” |
